Key Facts

Invested since 2013
Based in Berlin

About the company

OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.

Do you want to

know more about this company?

OMEICOS in the news

Zum Artikel

Press

16. April 2015

OMEICOS Therapeutics Raises EUR 6.2 Million in Series A to Advance Lead Candidate in Atrial Fibrillation

Zum Artikel

Press

12. December 2013

OMEICOS Therapeutics: Novel therapy for the treatment of atrial fibrillation

More startups from Life Sciences